PRESSRELEASES

27 September, 2022

Nanexa AB and Vitrivax, Inc reach agreement in principle

Today Nanexa AB and VitriVax, Inc. filed a notice with the Court requesting that Nanexa’s patent infringement lawsuit pending in the District of Delaware be stayed while the parties work to finalize settlement terms to which they have agreed in principle.

READ MORE

15 September, 2022

Nanexa launches NEX-22 product project to address a huge market

Nanexa AB (publ) announced today that it has decided to develop a long-acting formulation of liraglutide with PharmaShell® for the treatment of type 2 diabetes. NEX-22 will be the company’s third proprietary product development project.

READ MORE

LATEST REPORTS

PRESENTATIONS

2022-09-15

Webcast med kommentar och Q&A avseende start av projekt NEX-22 – Vd David Westberg och styrelseordförande Göran Ando svarar på frågor från analytiker och tittare.

2022-08-26

Webcast med Rapportkommentar, Delårsrapport jan-jun 2022.

2022-05-19

ABGSC Life Science Summit

MEET NANEXA

2022-10-25

Webcast med Rapportkommentar, Delårsrapport jan-sep 2022.

PRENUMERERA